Remdesivir to treat COVID-19: can dosing be optimized?

Jessica M. Conway; Pia Abel zur Wiesch

doi:10.1101/2021.06.16.21258981

Data Availability

Data employed in this study was previously published. The authors of this manuscript were not involved in the studies from which the data derived. Those studies are cited in the manuscript.

View the discussion thread.

Posted June 18, 2021.

Download PDF

Supplementary Material

Data/Code

Citation Tools

Subject Area

Pharmacology and Therapeutics

Subject Areas

All Articles

Addiction Medicine (417)
Allergy and Immunology (739)
Anesthesia (216)
Cardiovascular Medicine (3159)
Dentistry and Oral Medicine (353)
Dermatology (268)
Emergency Medicine (469)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1120)
Epidemiology (13128)
Forensic Medicine (15)
Gastroenterology (876)
Genetic and Genomic Medicine (4953)
Geriatric Medicine (456)
Health Economics (760)
Health Informatics (3114)
Health Policy (1112)
Health Systems and Quality Improvement (1153)
Hematology (417)
HIV/AIDS (984)
Infectious Diseases (except HIV/AIDS) (14426)
Intensive Care and Critical Care Medicine (894)
Medical Education (460)
Medical Ethics (121)
Nephrology (509)
Neurology (4704)
Nursing (249)
Nutrition (697)
Obstetrics and Gynecology (855)
Occupational and Environmental Health (771)
Oncology (2430)
Ophthalmology (690)
Orthopedics (272)
Otolaryngology (335)
Pain Medicine (313)
Palliative Medicine (88)
Pathology (523)
Pediatrics (1260)
Pharmacology and Therapeutics (533)
Primary Care Research (530)
Psychiatry and Clinical Psychology (4042)
Public and Global Health (7274)
Radiology and Imaging (1625)
Rehabilitation Medicine and Physical Therapy (972)
Respiratory Medicine (951)
Rheumatology (464)
Sexual and Reproductive Health (483)
Sports Medicine (409)
Surgery (526)
Toxicology (66)
Transplantation (223)
Urology (193)

Remdesivir to treat COVID-19: can dosing be optimized?

Data Availability

Citation Manager Formats

Subject Area